Transient Exposure of Enalapril Normalizes Prenatal Programming of Hypertension and Urinary Angiotensinogen Excretion

Asifhusen Mansuri¹, Ayah Elmaghrabi¹, Susan K. Legan¹, Jyothsna Gattineni¹, Michel Baum¹,²*

¹ Department of Pediatrics University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, ² Department of Internal Medicine University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

* Michel.Baum@UTSouthwestern.edu

Abstract

Maternal low protein diet programs offspring to develop hypertension as adults. Transient exposure to angiotensin converting enzyme inhibitors or angiotensin II receptor blockers can result in improvement in hypertension. Male rats whose mothers received a low protein diet during the last half of pregnancy were given either vehicle, continuous enalapril (CE) in their drinking water or were given transient enalapril exposure (TE) after weaning at 21 days of age. The TE group had enalapril in their drinking water for 21 days starting from day 21 of life. All rats were studied at 6 months of age. Vehicle treated rats whose mothers were fed a low protein diet were hypertensive, had albuminuria, and demonstrated upregulation of the intrarenal renin-angiotensin system as evidenced by higher urinary angiotensinogen and urinary angiotensin II levels. In low protein rats both continuous and transient exposure to enalapril normalized blood pressure, urinary angiotensinogen and urinary angiotensin II levels at 6 months of age, but only continuous administration of enalapril decreased urinary albumin excretion. These data support the importance of the intrarenal renin-angiotensin system in mediating hypertension in programmed rats and transient exposure to enalapril can reprogram the hypertension and dysregulation of the intrarenal renin-angiotensin system.

Introduction

Several epidemiological studies have demonstrated that small for gestational age infants are at risk for developing hypertension in later life [1–6]. Animal models have been utilized to examine the pathogenesis of the hypertension in prenatal programming. Offspring of rats whose mothers were administered a low protein diet, prenatal glucocorticoids or surgically induced reduced uterine perfusion develop hypertension as adults [7–12]. The cause for the hypertension has remained enigmatic.

The renin-angiotensin system is a major regulator of blood pressure and various components of the systemic and intrarenal renin-angiotensin system have been found to be affected...
in programmed rats [9,11–15]. Consistent with the renin-angiotensin system playing a role in mediating the hypertension in programming, studies have shown that both captopril, an angiotensin converting enzyme inhibitor, and losartan, an angiotensin II receptor blocker, administered to the drinking water from 2–4 weeks resulted in a reduction in blood pressure to levels comparable to the rats whose mothers were fed a normal protein diet [16,17]. Nifedipine, a calcium channel blocker did not affect blood pressure in programmed rats [16]. The antihypertensive effect of both captopril and losartan was still present at 12 weeks of age, 8 weeks after the drugs were discontinued [16,17]. Similarly, transient exposure to enalapril, an angiotensin converting enzyme inhibitor, from 3–6 weeks of age has been shown to reduce the blood pressure in offspring of mothers fed a low protein diet 10 weeks after the drug was discontinued [18]. The mechanism whereby transient administration of enalapril in programmed rats causes a sustained decrease in blood pressure is unknown. The purpose of this study was to examine whether the hypotensive effect of transient administration of enalapril is maintained into adulthood and to determine if there are components of the renin-angiotensin system that are reprogrammed by transient administration of enalapril that may explain how normalization of blood pressure is maintained despite discontinuing the angiotensin converting enzyme inhibition.

**Methods**

**Animals**

Pregnant Sprague Dawley rats were fed either a control diet containing 20% protein or an isocaloric 6% low protein diet from the 12th day of gestation until birth. This is the same protocol used by our laboratory and others to study the effect of prenatal programming on hypertension [8,19–24]. We have previously shown that the number of neonatal rats born to mothers who were fed the two diets was not different (11.4 ± 0.6 pups in the control vs 13.0 ± 0.5 pups in the low protein group, p = ns) [24]. Neonates were weaned at 21 days and all rats were then placed on a control diet. Rats were studied as adults and were from at least four different litters in each group. Only males were studied as they are affected by prenatal programming more severely than females and to reduce variability of the results [25–28]. These studies were approved by the IACUC (T-2011-0151) of the University of Texas Southwestern Medical Center.

After weaning the rats were separated into six groups:

1. **20% Vehicle (20%)**–The mother consumed a 20% protein diet while pregnant which was maintained while nursing and after birth. Four cc/L of ethanol was added to the drinking water of the offspring after weaning as the vehicle used to dissolve the enalapril from 3 weeks of age until time of study.

2. **6% Vehicle (6%)**- The mother consumed a 6% protein diet during the last half of pregnancy. The mother was then fed a 20% protein diet after giving birth and while nursing, as were the offspring after weaning. Four cc/L of ethanol was added to the drinking water after weaning as the vehicle used to dissolve the enalapril from 3 weeks of age until time of study.

3. **20% Continuous Enalapril (20%CE)**—After weaning the 20% protein fed rats were given enalapril (100 mg/L) in their drinking water continuously until the time of study [18].

4. **6% Continuous Enalapril (6%CE)**—After weaning the 6% protein fed rats were treated with enalapril (100 mg/L) in their drinking water continuously until the time of study.

5. **20% Transient Enalapril (20%TE)**—After weaning the 20% protein fed rats were given enalapril (100 mg/L) in their drinking water continuously for 21 days starting at 21 days of life and then placed on regular water containing ethanol vehicle.
6. 6% Transient Enalapril (6%TE)—After weaning the 6% protein fed rats were provided enalapril (100 mg/L) in their drinking water continuously for 21 days starting at 21 days of life and then placed on regular water containing ethanol vehicle.

Measurement of Blood Pressure
Blood pressure was measured in the 6 groups at 6 months of age. The investigator that measured the blood pressure was blinded as to which group the rat belonged. Rats were trained for 4 days for measurement of systolic blood pressure. Briefly rats were placed in Lucite tubes and a cuff was inflated several times so that the rats become accustomed to the procedure. The blood pressure was measured using tail cuff with a CODA Blood Non-Invasive Pressure Analyzer (Kent Scientific Corporation, Torrington, CT), which uses a volume pressure recording. Blood pressures measured with this system correlate well with blood pressure measurements obtained by telemetry [29]. The average of six blood pressure readings was used as the blood pressure for that rat.

Urine Collections
Rats were acclimatized to metabolic cages for three days with free access to food and water. Urine was then collected for 24 hours for measurement of creatinine, protein, albumin, angiotensinogen and angiotensin II. For the angiotensin II and angiotensinogen collection, the receptacle contained 50 μg pepstatin, 10 mg sodium azide, 300 nmol enalaprilat and, 125 μmol EDTA to prevent the degradation of angiotensinogen and angiotensin II as previously described [30–32]. The urine was stored at -80°C after collection.

Blood Collections
After measurement of blood pressure and the urine collection, blood was obtained by retro-orbital puncture. Rats were anesthetized with isoflurane and blood was collected with a heparinized capillary and placed in a chilled tube containing 20 μmol/l enalaprilat, 5 mmol/l EDTA, 10 μmol/l pepstatin A and 1 mmol/l 1,10-phenanthrolene (all chemicals were from Sigma Chemical Co., St. Louis, MO) to prevent peptide degradation [30–32]. The blood was centrifuged at 1,200 g for 10 min at 4°C and then stored at -80°C.

Urine and Blood Assays
Urine protein was measured using the Bradford assay (Bio-Rad Laboratories, Hercules, CA). Urine albumin was assayed using a Nephrat rat urinary albumin enzyme immunoassay kit (Exocell, Philadelphia, PA). Capillary electrophoresis was used to measure urine and serum creatinine.

For measurement of blood and urine angiotensin II, we used a protocol similar to that previously described by our laboratory [30,33,34]. Briefly, samples (2cc of urine or 0.1 cc of plasma) were loaded on to phenyl cartridges (Phenomenex, Torrance, CA). The angiotensin II was eluted from the cartridges with methanol, which was then dried under a stream of nitrogen. The residue was dissolved with EIA buffer and angiotensin II measured using an Angiotensin II Enzyme Immunoassay Kit from SPI-Bio (Montigny le Bretonneux, France). Urinary angiotensin II was measured in picogram per ml and results were reported in both picogram per 24 hours and also normalized to urine creatinine. Urine and plasma angiotensinogen was assayed using an ELISA kit (Rat Total Angiotensinogen Assay Kit, Immuno-Biological Laboratories Co, Minneapolis, MN). Urinary angiotensinogen was measured in nanogram per ml and
results were reported in both nanogram per 24 hours and angiotensinogen (ng) to creatinine (mg).

Plasma renin activity was measured with a Gamma Coat Plasma Renin Activity \(^{125}\text{I}\) RIA kit (DiaSorin Inc., Stillwater, MN) by assaying angiotensin I generation. Angiotensin I was then measured using a radioimmunoassay. Serum aldosterone was measured using an ELISA kit (Enzo Life Sciences, Farmingdale NY) as per the manufacturer's instructions.

Statistical Analysis

Data are shown as the mean ± the standard error of the mean. Comparisons between the groups were assessed using analysis of variance with a post hoc Student-Newman-Keuls test.

Results

In the first series of experiments we measured blood pressure in the 6 groups in a blinded fashion as shown in Fig 1. The blood pressure of the 6% vehicle group was higher than the 20% vehicle group as we have shown previously [8,19,20]. The 6% group that received continuous enalapril (6%CE) had a reduction in blood pressure to a value not different than the 20% group and the 20%CE group. Interestingly, the 6% transient enalapril group (6%TE) had a blood pressure comparable to the 20% and 20% TE groups despite the fact that they had not received enalapril for 20 weeks. The 20% continuous enalapril group had a lower blood pressure than the 20% group and the 6% and 20% transient enalapril groups.

To assess whether the hypertension in programming was mediated by dysregulation of the systemic renin-angiotensin system or if the systemic renin-angiotensin system was affected by enalapril, we measured plasma renin activity, angiotensin II and aldosterone in the 6 groups. As shown in Table 1, there was no difference in plasma angiotensinogen, plasma renin activity, angiotensin II and aldosterone levels in the programmed compared to the control rats.

Fig 1. Effect of continuous and transient enalapril on blood pressure in programmed rats.

Pregnant rats were given either a 20% protein diet or an isocaloric low protein diet during the last half of pregnancy. Nursing mothers were all given a 20% protein diet. Upon weaning at 3 weeks of age, rates were given enalapril (100 mg/L) or vehicle (ethanol 4 ml/L) in their drinking water. The continuous enalapril group (CE) received enalapril continuously until the time of study at 6 months of age. The transient enalapril group (TE) received enalapril from 3–6 weeks of age and vehicle thereafter. Blood pressure was measured by tail cuff after 4 days of training. The blood pressures were measured in a blinded fashion. The 6% group had a higher blood pressure than all the other groups. The continuous enalapril groups had a lower blood pressure than the corresponding transient enalapril group. N = 9–12 in each group.

doi:10.1371/journal.pone.0146183.g001
Continuous enalapril increased the renin level of both the 6% and 20% group (P<0.01), but neither transient nor continuous enalapril affected the levels of angiotensinogen, angiotensin II or aldosterone in any group.

The weights of the rats are shown in Table 2. The 6% groups weighed less than the 20% groups that were given the same postnatal treatment with vehicle, TE or CE (P<0.01). The continuous enalapril groups had less weight gain than the respective vehicle and TE groups (P<0.05). There was no difference in weight between the 6% group and the 20% CE group. The 20% CE group had a comparable weight to the 6% and 6% TE group and weighed less than the 20% TE and 20% group. This reduction in body weight was not seen in transient enalapril groups. The 20% group had comparable weight to the 20% TE group and the 6% group had a comparable weight to the 6% TE group.

We measured creatinine clearance in rats at 6 months of age. The results are shown in Table 2. The uncorrected creatinine clearance was lower in the 6% group compared to the 20% group using an unpaired t test (p<0.05), however when all groups were compared using analysis of variance there was no difference between the groups. Importantly, when the creatinine clearance was corrected for body weight, the values in all the groups were quite comparable. Thus, prenatal programming did not affect creatinine clearance at 6 months of age when the results were normalized for body weight and enalapril did not affect creatinine clearance in any group.

| Table 1. Effect of Continuous or Transient Enalapril on Systemic Renin-Angiotensin System in Control and Programmed Rats. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Angiotensinogen (ng/ml) | Renin (ng/ml/hr) | Angiotensin II (pg/ml) | Aldosterone (pg/ml) |
| 20% 8732 ± 302 | 2.7 ± 0.7 | 40.3 ± 8.2 | 224 ± 26 |
| 6% 7953 ± 704 | 2.7 ± 1.0 | 60.0 ± 19.5 | 268 ± 29 |
| 20%CE 7356 ± 516 | 31.4 ± 8.6 | 46.7 ± 7.0 | 310 ± 24 |
| 6%CE 8558 ± 462 | 34.8 ± 7.2 | 26.5 ± 5.7 | 285 ± 32 |
| 20%TE 8076 ± 665 | 1.6 ± 0.3 | 27.1 ± 5.9 | 373 ± 115 |
| 6%TE 7620 ± 489 | 2.0 ± 0.4 | 28.7 ± 9.7 | 204 ± 25 |

N = 9–15 in each group

doi:10.1371/journal.pone.0146183.t001

| Table 2. Effect of Continuous or Transient Enalapril on Creatinine Clearance and Urinary Protein Excretion in Control and Programmed Rats. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Body Weight gm | Creatinine Clearance (ml/min) | Creatinine Clearance/100gm BW | U Protein Excretion (mg/24h) | U Protein Excretion (mg/24hour/100gm BW) | U Albumin Excretion (mg/24h) | U Albumin Excretion (mg/24hour/100gm BW) |
| 20% 502 ± 19 | 2.72 ± 0.15 | 0.54 ± 0.03 | 57.8 ± 6.7 | 11.85 ± 1.3 | 5.7 ± 1.0 | 1.1 ± 0.2 |
| 6% 412 ± 10 | 2.03 ± 0.21 | 0.49 ± 0.05 | 69.3 ± 16.0 | 16.7 ± 3.8 | 24.9 ± 7.3 | 6.0 ± 1.8 |
| 20% CE 442 ± 5 | 2.44 ± 0.12 | 0.55 ± 0.03 | 20.1 ± 4.1 | 4.5 ± 0.9 | 1.4 ± 0.9 | 0.3 ± 0.2 |
| 6% CE 375 ± 10 | 2.11 ± 0.11 | 0.56 ± 0.02 | 25.2 ± 2.8 | 6.7 ± 0.6 | 4.9 ± 2.8 | 1.3 ± 0.6 |
| 20% TE 494 ± 21 | 2.78 ± 0.29 | 0.56 ± 0.06 | 44.0 ± 5.8 | 8.9 ± 1.2 | 10.2 ± 2.8 | 2.1 ± 0.6 |
| 6% TE 428 ± 11 | 2.60 ± 0.15 | 0.61 ± 0.03 | 51.8 ± 8.7 | 11.9 ± 7.8 | 19.2 ± 5.9 | 4.4 ± 1.4 |

N = 9–15 in each group

doi:10.1371/journal.pone.0146183.t002
Urinary protein and albumin excretion in the 6 groups are shown in Table 2. Urine protein excretion per 24 hours and per 24 hours normalized for body weight was not affected by prenatal programming. Continuous administration of enalapril resulted in a decrease in urinary protein excretion in both the 20% and the 6% protein groups (P < 0.05). There was a small reduction in protein excretion in the 20%TE group to a level less than the 6% group (P < 0.05). However, urinary albumin excretion per 24 hours and per 24 hours normalized per body weight was greater in the 6% group compared to the 20% group (P < 0.05). Continuous administration of enalapril resulted in a reduction in albumin excretion in the 6% group (6%CE) to a level less than the 6% group not treated with enalapril and the 6% TE group (P < 0.05). Transient administration of enalapril did not result in a significant reduction in urinary albumin excretion in programmed rats.

Urinary angiotensinogen has been shown to be a marker of the activity of the intrarenal renin angiotensin system [31,32,35]. In Fig 2, we show that urinary angiotensinogen is elevated in the 6% group compared to the 20% group as well as the continuous and transient enalapril groups whether normalized to the 24 hour urine volume (A) or urine creatinine concentration (B). Thus, the intrarenal renin-angiotensin system is increased in the programmed offspring which is normalized by continuous and transient treatment with enalapril. It should be noted that when comparing the 6 groups in Fig 2, there was no statistical differences in the urinary angiotensinogen in the 20% vehicle group compared to the 20% CE and 20% TE groups. However, if one compared the effect of enalapril on the 20% groups independent of the 6% groups, continuous and transient enalapril did decrease the urinary angiotensinogen excretion compared to the 20% vehicle group (p < 0.001).

We next examined if prenatal programming by maternal dietary protein restriction affected urinary excretion of angiotensin II and if urinary angiotensin II was affected by transient or continuous administration of enalapril. As shown in Fig 3, prenatal programming resulted in a significant increase in urinary angiotensin II excretion compared to the 20% control when normalized per 24 hour urine volume (A) or when normalized per urinary creatinine (B). Of importance, both continuous and transient administration of enalapril to the rats whose mothers were fed a low protein diet caused a significant reduction in urinary angiotensin II excretion.

Discussion

The present study examined whether the prenatal programming of hypertension due to maternal dietary protein deprivation was affected by enalapril. We find that both continuous and transient therapy with enalapril normalized the blood pressure in adult offspring due to
maternal dietary protein deprivation. The importance of this study is that the transient administration of enalapril can reprogram the hypertension seen with prenatal programming. The normalization of blood pressure in programmed rats had previously been demonstrated for 8–10 weeks after discontinuing either an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker [16–18]. In the present study the blood pressures were examined 20 weeks after discontinuing enalapril in the transient enalapril groups showing that the effect of transient enalapril remains well into adulthood.

We examined the effect of prenatal programming in offspring of mothers that were fed a low protein diet on creatinine clearance, protein and albumin excretion. While there was no effect of prenatal programming on urinary protein excretion in this study examining rats at 6 months of age, the programmed rats had a significantly greater urinary albumin excretion compared to the 20% controls. The decrease in creatinine clearance in the 6% group did not reach statistical significance compared to the other groups. We had previously examined if prenatal programming affected urinary protein and albumin excretion in offspring of mothers fed a low protein diet compared to those fed a normal protein diet. When studied at a year and a half of age we found that there was no effect of prenatal programming on either urinary protein or albumin excretion despite the fact that there was a significant decrease in glomerular filtration rate in the programmed rats [20]. With the progressive decline in glomerular filtration rate in programmed rats [20], it is not surprising that there is an increase in urinary albumin excretion in the current study. The reason for the lack of albuminuria in our previous study examining older rats is unclear. In this study we find that continuous but not transient enalapril treatment decreased albumin and protein excretion, which is consistent with the effect of angiotensin converting enzyme inhibitors to decrease glomerular capillary pressure [36].

Previous studies have examined the importance of the systemic renin-angiotensin system in the programming of hypertension [13]. There is some variability in how programming affects the systemic renin-angiotensin system, which is dependent on the nature of the prenatal insult and the time after birth when the renin-angiotensin system is assessed. Studies examining the effect of a maternal low protein diet have shown that plasma renin activity is lower at 4 weeks in programmed rats compared to controls, with a smaller but still significant reduction in plasma renin activity at 8 weeks of age [37]. This same group found higher levels of plasma renin activity in the low protein group compared to controls when studied at 16 weeks and 11 months of age [18,21]. Transient administration of enalapril normalized the plasma renin activity at 16 weeks in programmed rats [18]. Others have found no difference in plasma renin activity at 13 weeks in offspring of rats fed a low protein diet compared to a normal protein diet [38]. Comparable plasma angiotensin II levels are measured in programmed and control rats at 4 weeks of age and 13 weeks of age [38,39]. Aldosterone levels are higher in rats whose
mothers were fed a low protein diet at 4 weeks of age compared to controls and a smaller but significant increase was found at 8 weeks of age [37]. We have found a higher serum aldosterone level in rats whose mothers were fed a low protein diet at 4 months of age compared to controls and a corresponding increase in cortical collecting duct sodium transport in programmed rats [40]. Others have found a comparable aldosterone level at 16 weeks in programmed rats on a normal salt diet but a significantly higher level than control when the rats were placed on a high salt diet [18]. In the present study, we found no effect of maternal low protein diet on the offspring at 6 months of age and neither transient nor continuous enalapril affected the systemic angiotensin II or aldosterone levels. Plasma renin activity was comparably elevated in both the 6% and 20% group that received continuous but not transient enalapril. Consistent with our results, others have found that transient enalapril did not affect the levels of aldosterone in programmed rats [18].

Kobori et al. showed that urinary angiotensinogen is an indirect indicator of the intrarenal renin-angiotensin system and that urinary angiotensinogen levels correlate with intrarenal angiotensin II levels but not with plasma angiotensin II levels [31,32]. Urinary angiotensinogen and intrarenal angiotensin II increased with angiotensin II mediated hypertension but not in rats with hypertension treated with deoxycorticosterone acetate/high salt diet [31].

Previous studies have examined the effect of prenatal programming on the intrarenal renin-angiotensin system. Offspring of rats whose mothers were fed a low protein diet had comparable renal angiotensin I and angiotensin II levels at 28 days of age to offspring of rats fed a control diet [39]. Prenatal administration of dexamethasone programs offspring to develop hypertension [25,41]. There was a higher concentration of urinary angiotensin II/creatinine in programmed rats compared to controls [30]. Offspring of rats that were of low birth weight due to surgical reduction in uterine perfusion had reduced renal renin and angiotensinogen mRNA expression compared to controls at 1 day of age, but the programmed rats had significantly higher levels of both at 16 weeks of age [42]. There was no difference renal ACE mRNA or protein abundance at 16 weeks but the ACE activity was higher in programmed than control offspring [42]. Despite the evidence for increased renal angiotensin II production in the latter two studies, there was no demonstrable difference in renal angiotensin II content [30,42]. The reason for this discrepancy is not clear.

Recent studies had examined urinary angiotensinogen in neonates and as a marker of activation of the intrarenal renin angiotensin system in programmed rats. Urinary angiotensinogen/creatinine ratio was found to be higher in preterm than in full term neonates [43,44] and may serve as a marker for acute kidney injury [43]. Interestingly a study examined the effect of prenatal programming using a model of uterine artery ligation. At 32 weeks of age, programmed rats had no difference in plasma angiotensinogen compared to control rats, while, compared to controls, the programmed rats had significantly higher urinary angiotensinogen/creatinine levels at 20 and 32 weeks of age [45]. These findings are in concordance with our findings showing that prenatal programming has no effect on plasma angiotensinogen levels but causes a marked increase in urinary excretion of angiotensinogen.

In all of previous studies and the current study, the angiotensin converting enzyme inhibitor or angiotensin II receptor blocker was given to young animals at or near the time of weaning [16–18]. The effect of transient administration of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on blood pressure lasted for weeks after the drug has been discontinued. However, it is unclear if there is a window where this reprogramming of blood pressure can occur. It is unclear if transient administration of enalapril would continue to have an effect if administered to a programmed adult and how long the effect would last. It is also unknown if the effect of an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker will have a comparable effect in humans who are at risk for hypertension because of
being small for gestational age or very premature. Clearly, one cannot administer angiotensin converting enzyme inhibitor or angiotensin II receptor blockers during nephrogenesis in very premature infants because of the importance of the renin angiotensin system in renal development [46,47]. Whether one could administer an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker to humans to prevent hypertension at a time after renal development has occurred and for how long is unknown but of clinical importance. It should be noted that continuous administration of enalapril caused the rats to have a lower weight than the vehicle treated and the transient enalapril group. Whether this would occur in humans is unknown.

In summary, we demonstrate that there was a significant decrease in both urinary angiotensinogen and angiotensin II by continuous and transient administration of enalapril. These data are consistent with the intrarenal renin-angiotensin system playing a role in mediating the hypertension with prenatal programming. The fact that transient administration of enalapril can normalize blood pressure and urinary angiotensin II and urinary angiotensinogen levels suggest that there may be a window during postnatal development when prenatal programming can be reprogrammed.

Acknowledgments

This work was supported by NIH grant DK41612 and DK78596 to M.B, a grant from Children’s Medical Center and the O’Brien Center P30DK079328.

Author Contributions

Conceived and designed the experiments: MB JG AM. Performed the experiments: AM AE SL JG. Analyzed the data: AM AE SL JG MB. Wrote the paper: MB SL JG AM AE.

References

1. Eriksson JG, Forsen TJ, Kajantie E, Osmond C, Barker DJ (2007) Childhood growth and hypertension in later life. Hypertension 49: 1415–1421. PMID: 17452506
2. Barker DJ (2004) The developmental origins of adult disease. J Am Coll Nutr 23: 588S–595S. PMID: 15640511
3. Barker DJ (2004) The developmental origins of chronic adult disease. Acta Paediatr Suppl 93: 26–33.
4. Barker DJ (1996) The fetal origins of hypertension. J Hypertens Suppl 14: S117–S120. PMID: 9120668
5. Barker DJ, Osmond C (1988) Low birth weight and hypertension. BMJ 297: 134–135.
6. Law CM, Barker DJ, Bull AR, Osmond C (1991) Maternal and fetal influences on blood pressure. Arch Dis Child 66: 1291–1295. PMID: 1755640
7. Dagan A, Kwon HM, Dwarkanath V, Baum M (2008) Effect of renal denervation on prenatal programming of hypertension and renal tubular transporter abundance. Am J Physiol Renal Physiol 295: F29–F34. doi: 10.1152/ajprenal.00123.2008 PMID: 18400872
8. Mizuno M, Siddique K, Baum M, Smith SA (2013) Prenatal programming of hypertension induces sympathetic overactivity in response to physical stress. Hypertension 61: 180–186. HYPERTENSIONNAHA.112.199356 [pii]; doi: 10.1161/HYPERTENSIONAHA.112.199356 PMID: 23150514
9. Baum M (2010) Role of the kidney in the prenatal and early postnatal programming of hypertension. Am J Physiol Renal Physiol 298: F235–F247. doi: 10.1152/ajprenal.00288.2009 PMID: 19794108
10. Ingelfinger JR, Woods LL (2002) Perinatal programming, renal development, and adult renal function. Am J Hypertens 15: 46S–49S. PMID: 11866229
11. Vehaskari VM, Woods LL (2005) Prenatal programming of hypertension: lessons from experimental models. J Am Soc Nephrol 16: 2545–2556. PMID: 16049066
12. Alexander BT (2006) Fetal programming of hypertension. Am J Physiol Regul Integr Comp Physiol 290: R1–R10. PMID: 16352854
13. Kett MM, Denton KM (2011) Renal programming: cause for concern? Am J Physiol Regul Integr Comp Physiol 300: R791–R803. doi: 10.1152/ajpregu.00791.2010 PMID: 21191002

14. Langley-Evans SC, Sherman RC, Welham SJ, Nwagwu MO, Gardner DS, Jackson AA (1999) Intrauterine programming of hypertension: the role of the renin-angiotensin system. Biochem Soc Trans 27: 88–93. PMID: 10093713

15. Moritz KM, Cuffe JS, Wilson LB, Dickinson H, Wiodek ME, Simmons DG, et al. (2010) Review: Sex specific programming: a critical role for the renal renin-angiotensin system. Placenta 31 Suppl: S40–S46. S0143-4004(10)00022-6 [pii]; doi: 10.1016/j.placenta.2010.01.006 PMID: 20116093

16. Sherman RC, Langley-Evans SC (2000) Antihypertensive treatment in early postnatal life modulates prenatal dietary influences upon blood pressure in the rat. Clin Sci (Lond) 98: 269–275.

17. Sherman RC, Langley-Evans SC (1998) Early administration of angiotensin-converting enzyme inhibitor captopril, prevents the development of hypertension programmed by intrauterine exposure to a maternal low-protein diet in the rat. Clin Sci (Lond) 94: 373–381.

18. Manning J, Vehaskari VM (2005) Postnatal modulation of prenatally programmed hypertension by dietary Na and ACE inhibition. Am J Physiol Regul Integr Comp Physiol 288: R80–R84. PMID: 15458966

19. Mizuno M, Lozano G, Siddique K, Baum M, Smith SA (2014) Enalapril attenuates the exaggerated sympathetic response to physical stress in prenatally programmed hypertensive rats. Hypertension 63: 324–329. HypertensionAHA.113.02330 [pii]; doi: 10.1161/HYPERTENSIONAHA.113.02330 PMID: 24191284

20. Lozano G, Elmaghrabi A, Salley J, Siddique K, Gattineni J, Baum M (2015) Effect of Prenatal Programming and Postnatal Rearing on Glomerular Filtration Rate in Adult Rats. Am J Physiol Renal Physiol 308: 411–419. ajprenl.00593.2014 [pii]; doi: 10.1152/ajprenl.00593.2015

21. Manning J, Vehaskari VM (2001) Low birth weight-associated adult hypertension in the rat. Pediatr Nephrol 16: 417–422. PMID: 11405116

22. Dagan A, Habbib S, Gattineni J, Dwarakanath V, Baum M (2009) Prenatal Programming of Rat Thick Ascending Limb Chloride Transport by Low Protein Diet and Dexamethasone. Am J Physiol Regul Integr Comp Physiol 297: R93–99. doi: 10.1152/ajpregu.91006.2008 PMID: 19403862

23. Habbib S, Gattineni J, Twombley K, Baum M (2011) Evidence that prenatal programming of hypertension by dietary protein deprivation is mediated by fetal glucocorticoid exposure. Am J Hypertens 24: 96–101. doi: 10.1038/ajh.2010.177 PMID: 20725051

24. Habbib S, Zhang q, Baum M (2011) Prenatal Programming of Hypertension in the Rat: Effect of Postnatal Rearing. Nephron Extra 1: 157–165. doi: 10.1159/000333477 PMID: 22470389

25. Ortiz LA, Quan A, Zarzar F, Weinberg A, Baum M (2003) Prenatal dexamethasone programs hypertension and renal injury in the rat. Hypertension 41: 328–334. PMID: 12574103

26. Alexander BT (2003) Placental insufficiency leads to development of hypertension in growth-restricted offspring. Hypertension 41: 457–462. PMID: 12623943

27. Woods LL, Ingellfinger JR, Rasch R (2005) Modest maternal protein restriction fails to program adult hypertension in female rats. Am J Physiol Regul Integr Comp Physiol 289: R1131–R1136. PMID: 15961538

28. Moritz KM, Mazzuca MO, Siebel AL, Mibus A, Arena D, Tare M, et al. (2009) Uteroplacental insufficiency causes a nephron deficit, modest renal insufficiency but no hypertension with ageing in female rats. J Physiol 587: 2635–2646. doi: 10.1113/jphysiol.2009.170407 PMID: 19359373

29. Feng M, Whitesall S, Zhang Y, Beibel M, D’Alecy L, DiPetillo K (2008) Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 21: 1288–1291. ajh2008301 [pii]; doi: 10.1038/ajh.2008.301 PMID: 18846043

30. Dagan A, Gattineni J, Habbib S, Baum M (2010) Effect of prenatal dexamethasone on postnatal serum and urinary angiotensin II levels. Am J Hypertens 23: 420–424. doi: 10.1038/ajh.2009.274 PMID: 20075846

31. Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG (2003) Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension. Hypertension 41: 42–49. PMID: 12511528

32. Kobori H, Harrison-Bernard LM, Navar LG (2002) Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 61: 579–585. PMID: 11849399

33. Quan A, Chakravarty S, Chen JK, Chen JC, Loleh S, Saini N, et al. (2004) Androgens augment proximal tubule transport. Am J Physiol Renal Physiol 287: F452–F459. PMID: 15100096

34. Quan A, Baum M (1996) Endogenous production of angiotensin II modulates rat proximal tubule transport. J Clin Invest 97: 2878–2882. PMID: 8675701
35. Navar LG, Kobori H, Prieto-Carrasquero M (2003) Intrarenal angiotensin II and hypertension. Curr Hypertens Rep 5: 135–143. PMID: 12642013
36. Anderson S, Rennke HG, Brenner BM (1986) Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993–2000. PMID: 3011863
37. Vehaskari VM, Aviles DH, Manning J (2001) Prenatal programming of adult hypertension in the rat. Kidney Int 59: 238–245. PMID: 11135076
38. Langley-Evans SC, Jackson AA (1995) Captopril normalises systolic blood pressure in rats with hypertension induced by fetal exposure to maternal low protein diets. Comp Biochem Physiol A Physiol 110: 223–228. PMID: 7712066
39. Vehaskari VM, Stewart T, Lafont D, Soyez C, Seth D, Manning J (2004) Kidney angiotensin and angiotensin receptor expression in prenatally programmed hypertension. Am J Physiol Renal Physiol 287: F262–F267. PMID: 15100095
40. Cheng CJ, Lozano G, Baum M (2012) Prenatal programming of rat cortical collecting tubule sodium transport. Am J Physiol Renal Physiol 302: F674–F678. ajprenal.00633.2011 [pii]; doi: 10.1152/ajprenal.00633.2011
41. Ortiz LA, Quan A, Weinberg A, Baum M (2001) Effect of prenatal dexamethasone on rat renal development. Kidney Int 59: 1663–1669. PMID: 11318936
42. Grigore D, Ojeda NB, Robertson EB, Dawson AS, Huffman CA, Bourassa EA, et al. (2007) Placental insufficiency results in temporal alterations in the renin angiotensin system in male hypertensive growth restricted offspring. Am J Physiol Regul Integr Comp Physiol 293: R804–R811. PMID: 17537837
43. Wang Q, Li M, Li X, Pan J, Wang J, Feng X, Li Y (2015) Early urinary angiotensinogen excretion in critically ill neonates. J Renin Angiotensin Aldosterone Syst. 1470320315583777 [pii]; doi: 10.1177/1470320315583777
44. Suzue M, Urushihara M, Nakagawa R, Saijo T, Kagami S (2015) Urinary angiotensinogen level is increased in preterm neonates. Clin Exp Nephrol 19: 293–297. doi: 10.1007/s10157-014-0977-y PMID: 24792728
45. Murano Y, Nishizaki N, Endo A, Ikeda N, Someya T, Nakagawa M, et al. (2015) Evaluation of kidney dysfunction and angiotensinogen as an early novel biomarker of intrauterine growth restricted offspring rats. Pediat Res. pr2015153 [pii]; doi: 10.1038/pr.2015.153
46. Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA (2003) Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiology and Drug Safety 12: 633–646. PMID: 14762979
47. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. New England Journal of Medicine 354: 2443–2451. PMID: 16760444